Lumida
/GH
⌘K
Guardant Health Inc

Guardant Health Inc

GH
$155.87USD↑+0.56%+0.87 today

MARKET CAP

20.7B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$150 – $157

52W RANGE

$40
$174

AI Summary

Stalk
StalkMedium

GH is in a robust Stage 2 advance with a parabolic acceleration above rising EMAs, anchoring bullish medium- and long-term biases. However, extreme overbought conditions and an exhaustion candle near the peak suggest near-term timing is unfavorable. Execution should be deferred until a pullback into the rising EMA 9/21 support zone or prior consolidation range confirms renewed buying interest.

  • ↑Q1 2026 revenue reached $302M, a 48% YoY increase
  • ↑SHIELD revenue jumped to $42M from $6M YoY on 44,000 tests
  • ↓Q1 free cash flow burn increased to $71M from $67M last year
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Guardant Health, Inc. (NASDAQ: GH) is a pioneering leader in precision oncology, specializing in blood-based genomic testing solutions for cancer detection and monitoring. The company is positioned to leverage advancements in artificial intelligence and data analytics, particularly through its Guardant360 and SHIELD platforms, which emphasize early cancer detection and treatment optimization. As a key player in the oncology diagnostics landscape, Guardant Health is well-integrated into the growing trend towards non-invasive diagnostic methods.

Bull says

  • ↑Q1 2026 revenue reached $302M, a 48% YoY increase
  • ↑SHIELD revenue jumped to $42M from $6M YoY on 44,000 tests
  • ↑Full-year 2026 revenue guidance raised to $1.30–1.32B (+32–34%)
  • ↑Non-GAAP gross margin improved to 66% in Q1 2026
  • ↑Strategic Quest Diagnostics partnership broadens market access
  • ↑Strong growth factors, positive analyst revisions and high institutional backing

Bear says

  • ↓Q1 free cash flow burn increased to $71M from $67M last year
  • ↓Profitability metrics remain deeply negative, straining cash runway
  • ↓Stock trades at a 146% premium to intrinsic value (~$60)
  • ↓Insider selling of $52.7M signals potential leadership caution
  • ↓SHIELD expansion faces regulatory and reimbursement delays risk
  • ↓High rate sensitivity and negative book-to-price factors amplify downside

Investment themes with GH

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-11-2026bullish

Transcript signals

Bull points

  • Total revenue in Q1 increased 48% to $302 million, reflecting strong growth and continued momentum across oncology, biopharma, and data and screening.
  • Revenue increased 36% to $205 million.
  • Reveal remains our fastest-growing oncology product, with volume growth exceeding 100%, reflecting strong adoption in MRD and continued expansion in therapy response monitoring following its Q4 2025 launch.

Bear points

  • Non-GAAP operating expenses were $268 million, an increase of 34%, primarily driven by commercial investment.
  • Adjusted EBITDA loss in Q1 was $59 million, compared to a loss of $59 million in the first quarter of 2025.
  • Free cash flow burn in Q1 2026 was $71 million, compared to $67 million in the prior year period.
Read full transcript analysis ›